CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
27,700
-50 (-0.18%)
At close: Feb 27, 2026
73.23%
Market Cap 355.43B
Revenue (ttm) 2.13B
Net Income (ttm) -7.55B
Shares Out 12.83M
EPS (ttm) -589.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 161,535
Average Volume 267,199
Open 28,300
Previous Close 27,750
Day's Range 27,000 - 28,550
52-Week Range 14,420 - 42,200
Beta n/a
RSI 46.79
Earnings Date Mar 30, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.

Financial Statements

News

There is no news available yet.